Amgen Reply Brief Addresses Mischaracterizations by Sanofi, U.S. Government on Proper Enablement Inquiry for Genus Claims

“It is only when the number of combinations that do not work becomes a significant number that a really skilled craftsman is forced to ‘experiment too much’ to find one that actually exists or works, that ‘claims May actually be…








